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Errors in TCE Analysis
We read with interest the epidemiologic
overview and evaluation of trichloroethylene
(TCE) and cancer recently published by
Wartenberg et al. (1). Unfortunately, there
were a number of errors in Table 5 (1) con-
cerning risks reported in our study of workers
exposed to TCE during the manufacturing
of aircraft (2). For example, the standardized
mortality ratio (SMR) and the 95% confi-
dence interval (CI) presented for multiple
myeloma were actually those for Hodgkin’s
disease. There were also serious errors in the
listed SMR and CI for stomach cancer as
well as discrepancies in the presentation of
CIs for 10 other sites (Table 1). These
incorrect values were included in the meta-
analyses to make inferences regarding the
carcinogenic potential of TCE; thus, they
should be revised. 
We also found it peculiar that the
reported CIs from our study were recalcu-
lated. We computed exact CIs, which are
methodologically superior to the recalculat-
ed ones. The method of recomputation
assumed that our upper but not lower 
confidence limit was correct. These recom-
putations had the unusual property of exag-
gerating the lower CI, thus making the
results appear more statistically significant
(or closer to statistical significance) than
they actual were. 
John D. Boice, Jr.
Joseph K. McLaughlin
International Epidemiology Institute
Rockville, Maryland
E-mail: boice@iei.ws
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Errors in TCE Analysis:
Response
We thank Boice and McLaughlin for their
letter commenting on our paper (1). They
raise three types of issues with respect to
our reporting on their study: a) differences
between our reports of specific SMRs and
their original report; b) our report of no
data for a cancer site for which they report
no cases; and c) differences between our
reported confidence intervals (CIs) for their
standardized mortality ratios (SMRs) and
the CIs originally reported. We consider
each below.
The principal goal in our review was to
identify, critique, and summarize the cancer
epidemiology of trichloroethylene (TCE)-
exposed populations in a more complete
and systematic manner than that carried out
previously (2–4) while making our review
and averaging process as transparent as pos-
sible. We wanted to enable readers to
understand our methodology and to be able
to replicate our results or modify our
assumptions and make similar calculations
using our published tables (1,5). Therefore,
we reported in our tables the data input into
our SMR-averaging algorithm rather than
copying the exact values published in each
original study. We recognized at that time
that there were small differences, particular-
ly in the confidence intervals, but felt that
the transparency of our approach was of
greatest importance.
Our values for multiple myeloma and
stomach cancer were incorrect because we
had miscopied the SMRs from Boice et al.’s
paper (6). Using the point estimates pre-
sented by Boice et al. (7) and recalculating
the average SMRs, the average SMRs for
the Tier I mortality studies change from
1.9 (95% CI, 1.0–3.7) to 1.0 (95% CI,
0.6–1.9) for multiple myeloma and from
1.1 (95% CI, 0.8–1.6) to 1.3 (95% CI,
0.9–1.7) for stomach cancer. For these two
sites, the contribution of the Tier I mortali-
ty studies to our overall conclusions is quite
minimal. In our review, we suggested that
there is weak support for an association
between TCE and multiple myeloma, and
no evidence for an association between TCE
and stomach cancer (1). These conclusions
remain the same and are still valid in light of
the results from the Tier I incidence studies
and from the Tier II and Tier III studies. In
their letter, Boice and McLaughlin also
point out that the SMR for leukemia was
1.05 in contrast to that listed in Table 5 of
our paper (1) as 1.0. Risks that we present in
all tables in our paper are rounded, and the
difference between the data reported by
Boice et al. (6) and our data is due to an
unfortunate rounding error. Our calculation
of the average SMR for leukemia for the
Tier I mortality studies, however, uses the
value 1.05. Hence, the average SMR that is
in our published paper remains unchanged.
The second issue raised by Boice and
McLaughlin is for cervical cancer mortality
for which we report no information, where-
as Boice et al. (6) originally reported 0
observed cases with a 95% CI of 0.0–5.5.
This again reflects our desire for trans-
parency. We calculated the average risk by
combining the logarithm of the SMRs;
because log (0) is undefined, we could not
use these data in our calculation. The entry
in our table reflects how we handled the
data in our calculations rather than how the
data were reported originally. This also did
not affect our calculations.
The third issue raised by Boice and
McLaughlin is about the CIs for several of
the SMRs. In particular, they questioned
why we recalculated the CIs. Although we
recognize that exact CIs are superior to the
recalculated ones on statistical grounds, it is
not possible to directly determine the
underlying variance, a number we needed
for our average risk calculations. In most
cases, the CIs we calculated differ only
slightly from those in the published papers.
For example, in their Table 5, Boice et al.
(6) state that the lower confidence interval
for breast cancer is 0.6; in our paper (1), we
list it as 0.5. The reason that we recalculat-
ed the CIs is that to conduct the average
risk calculation using the Mantel-Haenszel
method, as reported in our paper (1), we
needed to calculate the variance of the
reported relative risk (RR):
where wi = 
To do so, we used the reported CI using the
following equations: 
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Table 1. Discrepancies between TCE and cancer
risks as reported by Boice et al. (2) and as listed
in Table 5 of the recent review by Wartenberg et
al. (1). 
Boice Wartenberg 
Cancer site et al. (2) et al. (1)
Multiple myeloma
SMR (no. cases) 0.9 (6) 2.8 (4)
95% CI (0.3–2.0) (1.1–7.1)
Stomach
SMR (no. cases) 1.3 (17) 0.8 (7)
95% CI (0.8–2.1) (0.4–1.7)
Cervix
SMR (no. cases) 0.0 (0) —
95% CI (0.0–5.5) —
Leukemia
SMR (no. cases) 1.1 (12) 1.0 (12)
95% CI (0.5–1.8) (0.6–1.8)
Breast
95% CI 0.5–2.7 0.6–2.7
Buccal
95% CI 0.2–1.4 0.3–1.4
Colon
95% CI 0.7–1.5 0.8–1.5
Esophagus
95% CI 0.3–1.7 0.4–1.7
Hodgkin’s disease
95% CI 0.8–7.1 1.1–7.1
Kidney
95% CI 0.4–2.0 0.5–2.0
Larynx
95% CI 0.3–2.8 0.4–2.8
Rectum
95% CI 0.6–2.5 0.7–2.5If the logarithm of the published upper and
lower CIs were not symmetric around the
ln(RR) (due to rounding errors or alterna-
tive calculation algorithms), we needed to
choose one for the calculations. Because
some of the lower CIs were 0, and the ln(0)
is undefined, we used the upper CI. For
consistency, we always used the upper CI to
calculate the variance. We then used this
variance to recalculate the lower CI. We
presented our recalculated values rather than
the original values because these were input
into the statistical averaging program. We
believe that this approach is more forthright
than reporting the investigators’ published
lower CI in our tables while using our recal-
culated lower CI in our average risk calcula-
tion. The procedure we used is described in
our paper (1). We cited Rothman and Boice
(7) for the above equations.
We apologize for the two typographic
errors and hope that our discussion adequate-
ly explains why the other numbers did not
exactly match the values originally published.
The views in this response are those of the authors
and do not necessarily reflect the views or policies of
the U.S. Environmental Protection Agency.
Daniel Wartenberg
Daniel Reyner
Environmental and Occupational Health
Sciences Institute
UMDNJ—Robert Wood Johnson
Medical School
Piscataway, New Jersey
E-mail: dew@eohsi.rutgers.edu
Cheryl Siegel Scott
U.S. Environmental Protection Agency
Washington, D.C.
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Toward Resolution of the
Divergent Effects of Estrogens
on the Prostate Gland of CF-1
Mice
In October 2000 an ad hoc panel of experts
was convened by the National Toxicology
Program and the U.S. Environmental
Protection Agency to review conflicting
reports of endocrine effects induced by low
doses of synthetic estrogens in rodents. Of
primary concern were reports by Nagel et al.
(1) and vom Saal et al. (2) of increases in
prostatic weight in CF-1 mice exposed in
utero to comparatively low doses of either
bisphenol A (BPA) or diethylstilbestrol
(DES), and subsequent reports by Cagen et
al. (3) and Ashby et al. (4) describing the
absence of such effects for both chemicals.
After the meeting it was realized that the
panel had failed to consider the work of
Nonneman et al. (5) from the vom Saal
group. Nonneman et al. (5) described the
influence of male intrauterine position (IUP)
on prostatic weight and suggested that dif-
ferences in estrogen levels between embryos,
according to their IUP, was responsible for
the differing prostatic weights observed.
That observation led to the evaluation of
synthetic estrogens in the CF-1 mouse.
Because the results of Nonneman et al. (5)
indicate that control prostate weights in the
CF-1 mouse are more variable than hitherto
thought, this variability should be taken into
account in evaluating the four sets of mouse
prostate data under discussion (1–4).
The panel noted, not for the first time,
that the CF-1 mouse control prostatic
weights reported by Ashby et al. (4) (49.1
mg, ~6 months of age) were significantly
heavier than those reported by Nagel et al.
(1) (~42 mg, ~6 months of age), vom Saal
et al. (2) (~42 mg, ~8 months of age), or
Cagen et al. (3) (~39 mg, 3.5 months of
age). In particular, the prostatic weights
reported by Nagel et al. (1) for animals
exposed to BPA (~55 mg) or reported by
vom Saal et al. (2) for animals exposed to
DES (~55 mg) were similar to the control
prostate weights reported by Ashby et al.
(4). In all of these studies, the IUP of the
male pups was not known: either one male
pup was selected randomly from the litter
(1,2) or all male pups were retained without
knowledge of IUP (3,4). vom Saal suggested
to the panel that the prostatic weights of the
mice used by Ashby et al. (4) may have been
increased by some unknown experimental
condition leading to a loss of sensitivity to
the two estrogens tested (1,2). In fact, our
animal body weights were higher than those
described by Nagel et al. (1), but vom Saal
et al. (6) reported that body weight is not
related to prostatic weight in CF-1 mice of
this age range (6). In contrast, the data
described by Nonneman et al. (5) may be
more relevant to our prostate weights.
Nonneman et al. (5) recorded prostate
weights for CF-1 mice at ~3.5 months of
age according to the IUP of the male pups.
These weights were as follows: 0M (adjacent
to no males) pups, 59.5 ± 3.3 mg (mean ±
SE of seven pups); 1M pups (adjacent to one
male), not reported; and 2M pups (adjacent
to two males), 49.4 ± 3.0 mg (5). From
these data, the average control prostate
weight for CF-1 mice in the vom Saal’s lab-
oratory in 1992 must have been > 50 mg,
which is greater than any of the control val-
ues discussed above (1–4). In addition, the
variability of control prostate weights in the
study by Nagel et al. (1) (SE = 1.0) is much
lower than would be expected based on the
data of Nonneman et al. (5) (SE ~3), a dif-
ference made more surprising by the fact
that knowledge of IUP would have been
expected to reduce, rather than increase, the
variability in IUP-specific prostatic weights.
The above considerations indicate two
things. First, that control prostate weights of
~49 mg reported by Ashby et al.(4),
although higher than recent values from the
laboratory of vom Saal (1,2,6), agree with
those reported in the only published refer-
ence to control CF-1 mouse prostate
weights presented according to IUP (5).
Second, given the dependency of prostate
weight on IUP (5), it would be of value to
statistically analyze the optimum study
design for the detection of a 30% increase
in prostatic weight, as reported for BPA (1).
In particular, it would be of value to estab-
lish how the use of seven test and seven con-
trol pups, each selected randomly from 14
dams without knowledge of IUP, could
have achieved such sensitivity. In conclu-
sion, the divergent findings for the prostate
gland of CF-1 mice (1–4) might be clarified
by publishing individual prostate weights
from earlier studies (1,2,5,6) in combina-
tion with an analysis of how IUPs of the
pups under study might affect those data.
John Ashby
Syngenta Central Toxicology Laboratory
Alderley Park, Cheshire, United Kingdom
E-mail: john.ashby@syngenta.com
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Prevalence of Headache
among Handheld Cellular
Telephone Users
Chia et al. (1) conducted a cross-sectional
community study in Singapore to deter-
mine the prevalence of central nervous sys-
tem (CNS) symptoms among hand-held
cellular telephone (HP) users compared to
nonusers. They found that headache was
the most prevalent symptom among HP
users compared to non-HP users, with an
adjusted prevalence rate ratio of 1.31 (95%
confidence interval, 1.00–1.70). Their study
was partly based on my data in a report of a
case series of symptomatic users (2).
However, they used the classification of
“primary headache disorders” provided by
the International Headache Society as their
case definition. This is at variance with my
original data in two ways: a) my subjects
reported that their symptoms related to
mobile phone use were quite different from
ordinary headaches, and b) their symptoms
were unilateral to side of use. These are 
clinical features that Chia et al. (1) did not
include in their analysis. The definition of
“headache” used by Chia et al. (1) would
lead to imprecision in case ascertainment
and hence a minimal estimate of the risk.
Bruce Hocking 
Specialist in Occupational Medicine
Camberwell, Victoria, Australia
E-mail: bruhoc@connexus.apana.org.au
REFERENCES AND NOTES
1. Chia SE, Chia HP, Tan JS. Prevalence of headache among
handheld cellular telephone users in Singapore: a commu-
nity study. Environ Health Perspect 108:1059–1062 (2000).
2. Hocking B. Preliminary report: symptoms associated
with mobile phone use. Occup.Med 48(6):357–360 (1998).
Prevalence of Headache
among Handheld Cellular
Telephone Users: Response
We would like to clarify that at no time was
our study (1) “based on [Hocking’s] data in a
report of a case series of symptomatic users....”
When we were discussing which factors
(symptoms) to study among hand-held cellu-
lar telephone users, Hocking's paper (2) is
only one of many to which we referred. 
Because ours was a community-based
study (1), we examined “specific CNS symp-
toms among handheld cellular telephone
users compared to nonusers.” Headache is
only one of the symptoms we studied. We
used the International Headache Society
Classification because it is commonly used
in publications related to headache; the use
of this classification would also enable
standardization and comparison with other
papers. Because our definition is different
from that of Hocking, we certainly cannot
analyze “unilateral to side of use” because
this information was not determined in our
study. We had no intention of confirming
or refuting Hocking’s report. In fact, we
made no reference to Hocking’s paper (2)
in the “Discussion” of our paper.
Therefore, we do not see how our defini-
tion of headache “would lead to impreci-
sion in case ascertainment and hence a
minimal estimate of the risk.” 
Sin-Eng Chia 
Hwee-Pin Chia 
Department of Community Occupational
& Family Medicine
National University of Singapore
Singapore, Republic of Singapore
E-mail: cofcse@nus.edu.sg
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Corrections and Clarifications
A meeting report by Sameeh A. Mansour
[Workshop Egyptox–2000: For Better
Environmental Education by the Birth of
the New Millennium. Environ Health
Perspect 109:197–198 (2001)] was inad-
vertantly omitted from the table of con-
tents of the February issue of EHP
(109:A57). We apologize for the omission.
➤ Toxicology of Fumonisin
➤ Assessment of Climate Variability and Change
➤ Migrant & Seasonal Farmworkers and Pesticide Exposure
➤ Inhaled Irritants and Allergens: Cardiovascular & Systemic Responses
➤ Pfiesteria: From Biology to Public Health
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